Tekla Life Sciences Investors
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.84
- Today's High:
- $12.935
- Open Price:
- $12.9
- 52W Low:
- $12.1636
- 52W High:
- $14.209
- Prev. Close:
- $12.92
- Volume:
- 125623
Company Statistics
- Market Cap.:
- $338.66 million
- Book Value:
- 16.124
- Revenue TTM:
- $3.51 million
- Operating Margin TTM:
- -63.85%
- Gross Profit TTM:
- $3.02 million
- Profit Margin:
- 156.45%
- Return on Assets TTM:
- -0.32%
- Return on Equity TTM:
- 1.28%
Company Profile
Tekla Life Sciences Investors had its IPO on 1992-05-04 under the ticker symbol HQL.
The company operates in the Financial Services sector and Asset Management industry. Tekla Life Sciences Investors has a staff strength of 0 employees.
Stock update
Shares of Tekla Life Sciences Investors opened at $12.9 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $12.84 - $12.94, and closed at $12.87.
This is a -0.39% slip from the previous day's closing price.
A total volume of 125,623 shares were traded at the close of the day’s session.
In the last one week, shares of Tekla Life Sciences Investors have slipped by -1.98%.
Tekla Life Sciences Investors's Key Ratios
Tekla Life Sciences Investors has a market cap of $338.66 million, indicating a price to book ratio of 0.961 and a price to sales ratio of 124.2319.
In the last 12-months Tekla Life Sciences Investors’s revenue was $3.51 million with a gross profit of $3.02 million and an EBITDA of $0. The EBITDA ratio measures Tekla Life Sciences Investors's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tekla Life Sciences Investors’s operating margin was -63.85% while its return on assets stood at -0.32% with a return of equity of 1.28%.
In Q3, Tekla Life Sciences Investors’s quarterly earnings growth was a negative -65.6% while revenue growth was a positive 34.4%.
Tekla Life Sciences Investors’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 129.2
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tekla Life Sciences Investors’s profitability.
Tekla Life Sciences Investors stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 124.2319.
Tekla Life Sciences Investors stock pays annual dividends of $1.3 per share, indicating a yield of 9.92% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $432.69 million
- Total Liabilities
- $0
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Tekla Life Sciences Investors ended 2024 with $432.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $432.69 million while shareholder equity stood at $422.65 million.
Tekla Life Sciences Investors ended 2024 with $0 in deferred long-term liabilities, $0 in other current liabilities, 262120.00 in common stock, $26.83 million in retained earnings and $0 in goodwill. Its cash balance stood at $822.00 and cash and short-term investments were $822.00. The company’s total short-term debt was $0 while long-term debt stood at $0.
Tekla Life Sciences Investors’s total current assets stands at $13640.00 while long-term investments were $432.64 million and short-term investments were $0. Its net receivables were $12818.00 compared to accounts payable of $0 and inventory worth $0.
In 2024, Tekla Life Sciences Investors's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Tekla Life Sciences Investors paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $12.87
- 52-Week High
- $14.209
- 52-Week Low
- $12.1636
- Analyst Target Price
- $
Tekla Life Sciences Investors stock is currently trading at $12.87 per share. It touched a 52-week high of $14.209 and a 52-week low of $14.209. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $13.07 and 200-day moving average was $13.33 The short ratio stood at 0.16 indicating a short percent outstanding of 0%.
Around 0.3% of the company’s stock are held by insiders while 1943.5% are held by institutions.
Frequently Asked Questions About Tekla Life Sciences Investors
Similar Industry Stocks (Asset Management)
Most Active
Top Gainers
Top Losers
About
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.